Pharmacotherapy for Alzheimer's disease: progress and prospects

被引:94
作者
Palmer, AM [1 ]
机构
[1] Pharmidex, London W1S 1RR, England
关键词
D O I
10.1016/S0165-6147(02)02056-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The number of people with Alzheimer's disease has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is, therefore, a substantial and increasing need for effective pharmacotherapy. Increased understanding of disease pathophysiology has led to palliative treatments for both cognitive and non-cognitive changes in behaviour. This, together with the prospect of drugs that slow or perhaps even halt the course of the disease, raises hope that this devastating disorder will soon be more amenable to pharmacotherapy with new drugs that either ameliorate specific symptoms or alter the course of the disease.
引用
收藏
页码:426 / 433
页数:8
相关论文
共 77 条
[1]   Role of locus coeruleus in attention and behavioral flexibility [J].
Aston-Jones, G ;
Rajkowski, J ;
Cohen, J .
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) :1309-1320
[2]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[3]   Brain choline acetyltransferase and mental function in Alzheimer disease [J].
Baskin, DS ;
Browning, JL ;
Pirozzolo, FJ ;
Korporaal, S ;
Baskin, JA ;
Appel, SH .
ARCHIVES OF NEUROLOGY, 1999, 56 (09) :1121-1123
[4]  
BEHL C, 2000, OXIDAT STRESS DIS, V5, P467
[5]   Effect of rivastigmine on scopolamine-induced memory impairment in rats [J].
Bejar, C ;
Wang, RH ;
Weinstock, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 383 (03) :231-240
[6]   Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? [J].
Benzi, G ;
Moretti, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 346 (01) :1-13
[7]  
Benzi G, 1988, EUR J PHARMACOL, V346, P1
[8]   Clinicopathologic studies in cognitively healthy aging and Alzheimer disease - Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype [J].
Berg, L ;
McKeel, DW ;
Miller, JP ;
Storandt, M ;
Rubin, EH ;
Morris, JC ;
Baty, J ;
Coats, M ;
Norton, J ;
Goate, AM ;
Price, JL ;
Gearing, M ;
Mirra, SS ;
Saunders, AM .
ARCHIVES OF NEUROLOGY, 1998, 55 (03) :326-335
[9]  
BIERER LM, 1995, J NEUROCHEM, V64, P749
[10]   Inherent abnormalities in energy metabolism in Alzheimer disease - Interaction with cerebrovascular compromise [J].
Blass, JP ;
Sheu, RKF ;
Gibson, GE .
VASCULAR FACTORS IN ALZHEIMER'S DISEASE, 2000, 903 :204-221